<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02789319</url>
  </required_header>
  <id_info>
    <org_study_id>DTS2016BSP-001-SubSDTS2016-01</org_study_id>
    <nct_id>NCT02789319</nct_id>
  </id_info>
  <brief_title>DTS Blood Glucose Monitor System Surveillance Program SubStudy 1</brief_title>
  <official_title>DTS Blood Glucose Monitor System Surveillance Program SubStudy 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diabetes Technology Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rainier Clinical Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AMCR Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Integrated Medical Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diablo Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Diabetes Technology Society</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The blanket protocol covers the execution of the Diabetes Technology Society (DTS) Blood
      Glucose Monitor System Surveillance Program that will consist of a series of similar accuracy
      sub-studies with marketed Blood Glucose Monitor Systems (BGMS) conducted by the Clinical and
      Laboratory site(s) chosen for this study. The two parts of the study (BGMS testing and
      comparative glucose analyzer testing) will be conducted in separate facilities (clinical site
      and laboratory site) so the clinical and laboratory investigators will be blinded from each
      other's results.

      To access the full protocol:
      http://dst.sagepub.com/content/early/2015/12/10/1932296815614587.full.pdf+html

      The clinical site(s) will recruit subjects and test their fingerstick blood directly on the
      Blood Glucose Monitor Systems. Tubes of fingerstick blood will also be collected from the
      same subjects, centrifuged and the plasma collected and frozen for shipment to a Clinical
      Laboratory Improvement Amendments (CLIA)/College of American Pathologists (CAP) certified,
      accredited clinical chemistry laboratory for measurement on a comparative glucose analyzer.
      In addition, National Institute of Standards and Technology (NIST) glucose standards (965b)
      will be assayed on the comparative glucose analyzers to determine any bias from the true
      glucose values established by the reference mass spectrometry method.

      This series of sub-studies will assess the accuracy of various BGMSs by trained
      professionals, not by the intended end user. Only accuracy of the BGMSs when tests are
      performed by trained study staff will be assessed. Understanding by the end user of
      instructions for use (labeling) and human factors analysis are not within the scope of this
      protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  This is a blanket protocol to cover a series of in vitro diagnostic, Phase 4,
           sub-studies to determine the performance of 18 various marketed blood glucose meter
           systems over a 12 month period. All activities performed in these sub-studies will fall
           within the parameters outlined in this protocol.

        -  At least 100 and not more than 125 subjects will participate in a sub-study

        -  All activities will be conducted according to Good Clinical Practice (GCP)

        -  The protocol, informed consent form, advertisements, and all appropriate documents, will
           be submitted to an Institutional Review Board (IRB) for approval prior to any study
           conduct.

        -  Informed consent will be obtained from each subject for each sub-study. The informed
           consent form for each sub-study will clearly identify and explain the specific
           procedures for that sub-study.

        -  All values obtained by the Blood Glucose Monitor Systems (BGMS) assayed at the clinical
           site will be compared with glucose values of plasma from the same subjects. Plasma
           samples will be properly prepared at the clinical site, frozen and shipped on dry ice to
           a Clinical Laboratory Improvement Amendments (CLIA) /College of American Pathologists
           (CAP) certified/accredited laboratory for analysis on a glucose comparative instrument

        -  Glucose Comparative instruments will be tested with appropriate manufacturers controls
           as well as with National Institute of Standards and Technology (NIST) 965b controls to
           assure accuracy and quality (analytical imprecision &lt; 2.9% a bias of &lt; 2.2%, and a total
           error &lt; 6.9%)

        -  Brief demographic and medical history information will be collected from subjects. In
           addition, information will be collected regarding medications taken in the previous 48
           hours by the subjects such as acetaminophen, ibuprofen, salicylate-containing drugs,
           ascorbic acid-containing drugs since such compounds could affect the testing results

        -  Trained study staff will perform both shallow and deep finger punctures on subjects
           using sterile lancing devices to obtain capillary blood for testing on the BGMSs, as
           well as for testing on a comparative glucose instrument - subjects will not be asked to
           do any self-testing

        -  Subject's capillary blood will be directly applied to the test strip of the BGMSs as per
           labeling of the device

        -  In some cases, subject's fingerstick blood will also be collected into a micro-tube and
           modified (for example, glycolyzed) to obtain blood samples in the hypoglycemic range not
           BGMSs that are oxygen insensitive since oxygen levels in blood can change during
           glycolysis.

        -  Testing of blood may include, but not limited to: -glucose concentration measured on
           BGMS, hematocrit, comparative glucose assay

        -  A volume of no greater than 2000 microliters of finger stick capillary blood will be
           obtained from any subject at a single visit to the site

        -  No more than ten finger punctures will be performed on any subject. The number and type
           of finger sticks that a subject may receive in each sub-study will be disclosed in the
           sub-study informed consent form. All lancets will be sterile; they may either be one
           time use devices, or lancing device with lancets that are generally used by people with
           diabetes for self-monitoring of their blood glucose. A new lancing device will be used
           on each subject.

        -  Study documents will be retained by the investigative clinical site, the clinical
           laboratory and Sponsor (Diabetes Technology Society) as required by GCP but no less than
           3 years following publication of results.

        -  Plasma from subjects will be shipped to the accredited clinical laboratory for assay
           using appropriate shipping methods for biological specimens

        -  A Contracted Research Organization (CRO) will oversee the studies, monitor the clinical
           and laboratory sites, conduct Part 11 compliant data management, perform statistical
           analysis, create reports and post results on clintrials.gov and on the DTS Blood Glucose
           Monitor System Surveillance Program website that will be created.

      To access the full protocol:
      http://dst.sagepub.com/content/early/2015/12/10/1932296815614587.full.pdf+html
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analytical accuracy and clinical performance criteria</measure>
    <time_frame>up to 2 months</time_frame>
    <description>Determine if blood glucose monitoring systems marketed in the US meet pre-determined analytical 199 accuracy and clinical performance criteria. Analytical accuracy/clinical performance criteria were 200 determined by consensus of the DTS BGMS Surveillance Program Steering Committee.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device issues</measure>
    <time_frame>up to 2 months</time_frame>
    <description>Obtain data on BGMS device failures or device related problems that may occur during the study</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Results</measure>
    <time_frame>up to 2 months</time_frame>
    <description>Provide study results to all interested parties through creation of the DTS BGMS Surveillance 205 Website</description>
  </other_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Actual">1220</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>FreeStyle Lite</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood Glucose Meter type</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Contour Next</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood Glucose Meter type</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OneTouch Ultra2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood Glucose Meter type</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACCU-CHEK AVIVA Plus</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood Glucose Meter type</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prodigy Auto Code</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood Glucose Meter type</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Walmart ReliOn Prime</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood Glucose Meter type</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Embrace</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood Glucose Meter type</description>
  </arm_group>
  <arm_group>
    <arm_group_label>True Result</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood Glucose Meter type</description>
  </arm_group>
  <arm_group>
    <arm_group_label>True Track</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood Glucose Meter type</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Walmart ReliOn Confirm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood Glucose Meter type</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Advocate Redi-Code +</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood Glucose Meter type</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CVS Advanced</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood Glucose Meter type</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OneTouch Verio</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood Glucose Meter type</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Contour</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood Glucose Meter type</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Accu-Chek Nano</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood Glucose Meter type</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Walmart ReliOn Ultima</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood Glucose Meter type</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gmate Smart</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood Glucose Meter type</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SolusV2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood Glucose Meter type</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blood Glucose Meter Systems</intervention_name>
    <arm_group_label>FreeStyle Lite</arm_group_label>
    <arm_group_label>Contour Next</arm_group_label>
    <arm_group_label>OneTouch Ultra2</arm_group_label>
    <arm_group_label>ACCU-CHEK AVIVA Plus</arm_group_label>
    <arm_group_label>Prodigy Auto Code</arm_group_label>
    <arm_group_label>Walmart ReliOn Prime</arm_group_label>
    <arm_group_label>Embrace</arm_group_label>
    <arm_group_label>True Result</arm_group_label>
    <arm_group_label>True Track</arm_group_label>
    <arm_group_label>Walmart ReliOn Confirm</arm_group_label>
    <arm_group_label>Advocate Redi-Code +</arm_group_label>
    <arm_group_label>CVS Advanced</arm_group_label>
    <arm_group_label>OneTouch Verio</arm_group_label>
    <arm_group_label>Contour</arm_group_label>
    <arm_group_label>Accu-Chek Nano</arm_group_label>
    <arm_group_label>Walmart ReliOn Ultima</arm_group_label>
    <arm_group_label>Gmate Smart</arm_group_label>
    <arm_group_label>SolusV2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, 18 years of age and older

          -  People with type 1 or type 2 diabetes, and no diabetes

          -  At least 66% of subjects will have diabetes

          -  Approximately 33% of subjects will not have a diagnosis of diabetes (but may have
             pre-diabetes or previous gestational diabetes)

          -  Able to speak, read and understand informed consent form in English (unless informed
             consent forms in other languages become available)

        Exclusion Criteria:

          -  Hemophilia or any other bleeding disorder

          -  Pregnancy (to eliminate any potential negative effects from the testing procedure on
             this population, and to reduce liability to the site and sponsor)

          -  If potential subject has already participated in 4 previous sub-studies in the past 12
             months

          -  A condition, which in the opinion of the investigator or designee, would put the
             person or study at risk (reason for exclusion will be documented)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Diabetes Technology Society</name>
      <address>
        <city>Burlingame</city>
        <state>California</state>
        <zip>94010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMCR Institute</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://dst.sagepub.com/content/early/2015/12/10/1932296815614587.full.pdf+html</url>
    <description>Protocol</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>May 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2016</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood Glucose Monitoring System</keyword>
  <keyword>BGMS</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Patient Use</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

